{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Local Recurrence"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"No Local Recurrence"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"The number of patients with local recurrence after a median follow-up of 24 months. Local recurrence is defined as disease progression (new cancer growth) at the primary cancer site.","groups":[{"description":"Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT)\n\nBevacizumab: Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses\n\nRadiation Therapy: External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good.\n\nSurgery: Surgery is performed 6-7 weeks after completion of neoadjuvant therapy.","id":"OG000","title":"Bevacizumab, Radiation, and Surgery"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"3 years","title":"Local Control Rate","type":"SECONDARY","unitOfMeasure":"Participants"}